Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study
JCO Precis Oncol
oregon; portland; ppmc; Humans; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Mutation; Receptor, ErbB-2; Trastuzumab
PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from a cohort of patients with lung cancer and
METHODS: Eligible patients had advanced lung cancer of any histology, no standard treatment options, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and tumors with
RESULTS: Twenty-eight patients with lung cancer (27 non-small-cell, 1 small-cell) and
CONCLUSION: Combination P + T showed evidence of antitumor activity in heavily pretreated patients with non-small-cell lung cancer and
Ganti, Apar K; Rothe, Michael; Mangat, Pam K; Garrett-Mayer, Elizabeth; Dib, Elie G; Duvivier, Herbert L; Ahn, Eugene R; Behl, Deepti; Borghaei, Hossein; Balmanoukian, Ani S; Gaba, Anu; Li, Rui; Osei-Boateng, Kwabena; Thota, Ramya; Grantham, Gina N; Gregory, Abigail; Halabi, Susan; and Schilsky, Richard L, "Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study" (2023). Articles, Abstracts, and Reports. 7468.